Pipeline · Neurology & Neuropsychiatry

Autism (ASD) Unified.Phase II

Unified ASD + Seizure + Tourette protocol. Four convergent mechanisms: E/I imbalance, neuroinflammation, CSTC/basal-ganglia circuit, gut-brain / 5-HT. Blend TRI-01 lead candidate. Phase IIa N=30, 16-week protocol.

Status: Phase II
Therapeutic area: Neurology & Neuropsychiatry
Key: 14 compounds · TRI-01 lead

The mechanism we're betting on.

Unified ASD + Seizure + Tourette protocol. Four convergent mechanisms: E/I imbalance, neuroinflammation, CSTC/basal-ganglia circuit, gut-brain / 5-HT. Blend TRI-01 lead candidate. Phase IIa N=30, 16-week protocol. The full mechanism map — including compound list, dose escalation, pre-specified biomarker thresholds, and the cross-walk modifiers used when re-fitting blends from related indications — is part of the gated methodology pack.Gated

What the rest of the world is doing.

Numbers below are surfaced by Atlas Bio's ClinicalTrials.gov and PubMed RWE pipelines, run against the Autism (ASD) Unified indication. Counts are industry-wide trials registered on ClinicalTrials.gov, not Atlas Bio studies. Methodology →

Locked before readout.

Predictions for this study are SHA-256 locked before any readout. Pre-registration covers target engagement, primary endpoint, secondary endpoints, and the falsification criterion. The hash, prediction wording, and timestamp are available to verified clinicians and indication researchers on request.Gated

Same stack, every indication.

Want the full Autism (ASD) Unified protocol?

The abstract above is open. Compound lists, dose escalations, SHA-256-locked prediction documents, agent-network reasoning chains, and trial design specifics are available to verified clinicians, indication researchers, and sponsors under MNDA. Contact management to begin the access request.

Contact management →